S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NYSEARCA:PRME

Prime Medicine - PRME Stock Forecast, Price & News

$16.86
-0.64 (-3.66%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.56
▼
$17.44
50-Day Range
$15.20
▼
$21.12
52-Week Range
$14.52
▼
$21.73
Volume
110,849 shs
Average Volume
336,949 shs
Market Capitalization
$1.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.25
Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer First Trust
Fund NameFirst Trust Heitman Global Prime Real Estate ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:PRME
Inception Date11/12/2015
Fund ManagerJerry Ehlinger, John White, Jacques Perdrix, Andreas Welter
Webwww.primemedicine.com
Phone617-465-0013

Fund Focus

Asset ClassReal Estate
BenchmarkNot Applicable
CategoryReal Estate
FocusReal Estate
Development LevelBlended Development
RegionGlobal

Fund Statistics

Assets Under Management$1.03 million
Average Daily Volume$213.00
Discount/Premium3.91%

ETF Expenses

Management Fee0.95%
Other Expenses0.00%
Total Expenses0.95%
Fee Waiver0.00%
Net Expenses0.95%

Administrator, Advisor and Custodian

AdministratorBrown Brothers Harriman & Co.
AdvisorFirst Trust Advisors L.P.
CustodianBrown Brothers Harriman & Co.
DistributorFirst Trust Portfolios L.P.
Transfer AgentBrown Brothers Harriman & Co.
Trustee
Lead Market MakerCredit Suisse

Key Executives

  • Dr. Keith Michael Gottesdiener M.D. (Age 68)
    Pres, CEO, Sec. & Director
    Comp: $867.11k
  • Dr. Ann L. Lee Ph.D. (Age 60)
    Chief Technical Officer
    Comp: $171.19k
  • Dr. Jeremy S. Duffield M.D. (Age 54)
    Ph.D., Chief Scientific Officer
    Comp: $994.4k
  • Dr. Andrew Anzalone M.D. (Age 36)
    Ph.D., Co-Founder, Sr. Scientist II, Head of Prime Editing Platform & Head of Platform Devel.
  • Dr. David R. Liu Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Ms. Carman Alenson C.P.A. (Age 57)
    M.B.A., Chief Accounting Officer & Interim CFO
  • Dr. Meredith Goldwasser (Age 51)
    Sr. VP of Strategy & Corp. Operations and Head of Strategy & Corp. Operations
  • Dr. Karen Brown J.D.
    Ph.D., Sr. VP of Intellectual Property & Legal Affairs
  • Ms. Niamh Alix
    Chief HR Officer
  • Mr. Richard Brudnick (Age 65)
    Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PRME Stock - Frequently Asked Questions

Should I buy or sell Prime Medicine stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRME shares.
View PRME analyst ratings or view top-rated stocks.

What is Prime Medicine's stock price forecast for 2023?

4 brokerages have issued 1-year price targets for Prime Medicine's stock. Their PRME share price forecasts range from $22.00 to $27.00. On average, they expect the company's stock price to reach $24.25 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price.
View analysts price targets for PRME or view top-rated stocks among Wall Street analysts.

How have PRME shares performed in 2022?

Prime Medicine's stock was trading at $20.23 at the beginning of the year. Since then, PRME shares have decreased by 16.7% and is now trading at $16.86.
View the best growth stocks for 2022 here.

What is Prime Medicine's stock symbol?

Prime Medicine trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "PRME."

When did the company's quiet period expire?

Prime Medicine's quiet period expired on Tuesday, November 29th. Prime Medicine had issued 10,294,118 shares in its initial public offering on October 20th. The total size of the offering was $175,000,006 based on an initial share price of $17.00. During the company's quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Prime Medicine?

Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prime Medicine's stock price today?

One share of PRME stock can currently be purchased for approximately $16.86.

How much money does Prime Medicine make?

Prime Medicine (NYSEARCA:PRME) has a market capitalization of $1.59 billion.

How can I contact Prime Medicine?

The official website for the company is www.primemedicine.com. The company can be reached via phone at 617-465-0013.

This page (NYSEARCA:PRME) was last updated on 12/8/2022 by MarketBeat.com Staff